Bioxyne LimitedASX: BXN

Appendix 4C Revised

· Issued by Bioxyne Limited

Filed with ASX · · 12 pages · English

Summary by 6ix AI

The report highlights record quarterly revenue and cash receipts, alongside positive cash flow from operating activities. Key agreements were established, including partnerships for the import and manufacture of medicinal cannabis products, positioning the company for growth in emerging markets. The filing also notes the successful dual listing on the Frankfurt Stock Exchange, enhancing access for European investors.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

• Record $18.4 million quarterly Cash Receipts, representing a 149% increase on Q2 FY25 and a 43% increase on Q1 FY26. • $2.5 million positive Q2 cash flow from operating activities • Completed dual listing on the Frankfurt Stock Exchange (ticker: PR8.F) on 13 October 2025, enhancing liquidity and access for European investors • Executed exclusive import, manufacture, and supply agreement with Cur

Bioxyne Limited on 6ix

In the deck

Story so far

Earlier from Bioxyne

Later from Bioxyne

All Bioxyne news releases